Clearance Summary
Advanta VXT Vascular Graft, Flixene Vascular Graft received FDA 510(k) clearance under submission number K231972, sponsored by Atrium Medical Corporation. The device was reviewed via the Traditional premarket notification pathway and assigned to the Cardiovascular review panel. The statutory decision date of record is 2024-03-28.
- Submission: K231972
- Applicant / Sponsor: Atrium Medical Corporation
- Clearance pathway: Traditional
- Review panel: Cardiovascular
- Device class: Class II
- Regulation citation: 21 CFR 870.3450
- Decision date: 2024-03-28
Classification & Regulation
This clearance is catalogued under FDA product code DSY and 21 CFR 870.3450, within the Cardiovascular review panel as a Class II device.